Bionic nano-liposome for targeting experimental autoimmune neuritis as well as preparation method and application of bionic nano-liposome
By encapsulating the shell cysts B and rhodiolitin in bionic nanoliposomes of experimental autoimmune neuritis and modifying the bionic cell membrane, the limited efficacy of Guillambare syndrome and drug bioavailability are solved. The problem of low results in targeted drug delivery and immune balance, significantly alleviating the progress of neuritis.
Patent Information
- Application Number
- CN202411033473.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-30
- Publication Date
- 2024-11-08
AI Technical Summary
The existing treatment methods for Guillambare syndrome have problems with limited efficacy and low drug bioavailability, especially the expensive price of cystsporin B and the short half-life of rhodiolisin in the body, which limits its disease treatment. Application.
Develop a bionic nanoliposome targeting experimental autoimmune neuritis, which encapsulates the bionic cell membrane in the outer layer of liposomes carrying cassoposporin B and rhodiolisine, and modifys phospholipidation on the surface of the bionic cell membrane Hyaluronic acid forms a nanocarrier with the effect of bionic membrane immune escape, improving the biocompatibility and targeting of drugs.
Targeted delivery of drugs to inflammatory nerve sites is achieved, immune balance is regulated, peripheral nerve repair is promoted, drug circulation half-life is prolonged, bioavailability is improved, toxic side effects are reduced, and the progress of experimental autoimmune neuritis is significantly alleviated.
Smart Images

Figure CN118903465A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedicine, and specifically relates to a bionic nanoliposome targeting experimental autoimmune neuritis, and a preparation method and application thereof. Background Art
[0002] Neurological diseases are one of the diseases that seriously endanger human health. The treatment, regeneration and functional recovery of nerve damage are historical problems in the medical field. Guillain-Barré syndrome (GBS) is a post-infectious autoimmune-mediated peripheral nervous system disease. Its symptoms usually manifest as muscle weakness, which starts from the lower limbs and gradually rises, and may eventually involve the muscles that support breathing, circulation and digestion. In severe cases, neck muscle and respiratory muscle weakness may occur, leading to difficulty breathing. At present, the main treatments for Guillain-Barré syndrome include intravenous immunoglobulin (IVIG) and plasma exchange (PE). Despite standard immunotherapy, about 5% of people still die, and up to 20% of people cannot walk independently one year after the onset of the disease. Although simple immune regulation can play a therapeutic role, it has little effect on the repair of damaged peripheral nerves.
[0003] The exact pathogenesis of GBS has not been fully elucidated, and the experimental model of GBS is crucial for understanding its pathological mechanism and developing new treatments. Experimental autoimmune neuritis (EAN) is a commonly used animal model of GBS, which can simulate multiple pathological features of GBS, including inflammation and demyelination of peripheral nerves, and infiltration of immune cells. The EAN model induces an immune response in animals by injecting specific antigens, such as gangliosides or peptides, which in turn causes nerve damage. This model is helpful for studying the immunopathological mechanism of GBS, including the role of Th1 and Th17 cells, and the effects of cytokines such as tumor necrosis factor α (TNF-α) and interferon γ (IFN-γ). Although EAN is an experimental model, it is of great significance for studying the pathological process of Guillain-Barré syndrome and developing new treatments. Drugs with targeted therapeutic effects on experimental autoimmune neuritis (EAN) have great potential for the treatment of Guillain-Barré syndrome.
[0004] Cytosporone B (CSNB) is a natural agonist of NR4A1. Existing studies (Yu, H., et al., NR4A1 agonist cytosporone B attenuates neuroinflammation in a mouse model of multiple sclerosis. Neural Regeneration Research, 2022. 17 (12): p. 2765.) suggest that CSNB can inhibit the differentiation of Th1 and Th17 cells, increase the polarization of macrophages toward anti-inflammatory phenotypes, and has the effect of regulating immunity and inhibiting inflammation. Salidroside (SAL) is the main active ingredient of Rhodiola rosea and has neuroprotective activity. Studies have shown that (Li, J., et al., Salidroside promotes sciatic nerve regeneration following combined application epimysium conduit and Schwann cells in rats. Exp Biol Med (Maywood), 2020. 245 (6): p. 522-531. or Liu, H., et al., The Proliferation Enhancing Effects of Salidroside on Schwann Cells In Vitro. Evidence-Based Complementary and Alternative Medicine, 2017. 2017: p. 1-10.) Salidroside can promote the proliferation of Schwann cells in vitro and the regeneration of sciatic nerve in rats. However, it is still unknown whether cystosporin B and salidroside can improve the occurrence and development of experimental autoimmune neuritis. At the same time, CSNB is expensive, SAL has a short half-life in the body, low bioavailability, and is easily affected by light, temperature, etc. during the pharmaceutical process, which limits their application in disease treatment.
[0005] Biomimetic nanoliposomes are a new type of drug delivery system that improves the biocompatibility, targeting and therapeutic efficiency of drugs by mimicking the cell membrane structure. This technology uses different types of cell membranes to modify nanocarriers, such as the membranes of red blood cells, platelets, stem cells, macrophages, tumor cells and bacteria, thereby giving nanocarriers better in vivo circulation time and targeting. However, how to obtain a biomimetic nanoliposome that targets experimental autoimmune neuritis and has a therapeutic effect on autoimmune neuritis requires further research. Summary of the invention
[0006] The purpose of the present invention is to provide a bionic nanoliposome targeting experimental autoimmune neuritis and a preparation method and application thereof.
[0007] The invention provides a bionic nanoliposome targeting experimental autoimmune neuritis, which is obtained by wrapping a bionic cell membrane on the outer layer of a liposome carrying cystosporin B and salidroside, and then modifying the surface of the bionic cell membrane with phospholipidated hyaluronic acid.
[0008] Furthermore, the preparation method of the liposome containing cystosporin B and salidroside comprises the following steps:
[0009] (1) dissolving soybean lecithin, cholesterol and cystosporin B in an organic solvent, and removing the organic solvent after rotary evaporation to obtain a film;
[0010] (2) Adding a hydrating medium containing salidroside into the film for hydration to obtain the film.
[0011] Further,
[0012] In step (1), the mass ratio of soybean lecithin to cholesterol is (2-4):1;
[0013] And / or, in step (1), the mass ratio of soybean lecithin to cystosporin B is (5-20):1;
[0014] And / or, in step (1), the organic solvent is chloroform or methanol;
[0015] And / or, in step (2), the mass ratio of salidroside to the soybean lecithin in step (1) is 1:(1-4);
[0016] And / or, in step (2), the volume mass ratio of the hydration medium containing salidroside to soybean lecithin is (1-4) ml:2 mg;
[0017] Preferably,
[0018] In step (1), the mass ratio of soybean lecithin to cholesterol is 2:1;
[0019] And / or, in step (1), the mass ratio of soybean lecithin to cystosporin B is 10:1;
[0020] And / or, in step (2), the mass ratio of salidroside to the soybean lecithin in step (1) is 1:2;
[0021] And / or, in step (2), the volume mass ratio of the hydration medium containing salidroside to soybean lecithin is 1 ml:2 mg.
[0022] Further,
[0023] In step (2), the hydration medium is a phosphate buffer with a pH of 7.4;
[0024] And / or, in step (2), after hydration, the solution is filtered through a microporous filter membrane with a particle size of 0.22 μm.
[0025] Furthermore, the bionic cell membrane is a macrophage membrane.
[0026] Furthermore, the preparation method of the phospholipidated hyaluronic acid comprises the following steps:
[0027] Hyaluronic acid, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide, N-hydroxysuccinimide and DSPE-PEG2000-NH 2 Dissolve in PBS buffer and stir to react, dialyze and freeze-dry to obtain;
[0028] Preferably,
[0029] The hyaluronic acid, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide, N-hydroxysuccinimide and DSPE-PEG2000-NH 2 The mass ratio is 1:(1-5):(1-10):5;
[0030] And / or, the reaction temperature is 25-40°C.
[0031] The present invention also provides a method for preparing the aforementioned bionic nanoliposome, which comprises the following steps:
[0032] 1) mixing the liposomes loaded with cystosporin B and salidroside with the PBS buffer of the bionic cell membrane and stirring to obtain the liposomes with the outer layer wrapped with the bionic cell membrane;
[0033] 2) Mix the liposomes with the bionic cell membrane wrapped in the outer layer with the PBS buffer solution of phospholipidated hyaluronic acid and stir to obtain a liposome.
[0034] Further,
[0035] In step 1), the mass ratio of soybean lecithin to bionic cell membrane in the liposome is (10-20):1;
[0036] And / or, in step 1), the stirring temperature is 25-37° C., the rotation speed is 800-1000 rpm, and the time is 1-4 hours;
[0037] And / or, in step 2), the mass ratio of soybean lecithin to phospholipidated hyaluronic acid in the liposome is (20-60):1;
[0038] And / or, in step 2), the stirring temperature is 25-37°C, the rotation speed is 800-1000 rpm, and the time is 0.5-2 hours;
[0039] Preferably,
[0040] In step 1), the mass ratio of soybean lecithin to bionic cell membrane in the liposome is 10:1;
[0041] And / or, in step 2), the mass ratio of soybean lecithin to phospholipidated hyaluronic acid in the liposome is 20:1.
[0042] The present invention also provides the use of the aforementioned bionic nanoliposome in the preparation of a drug for preventing and / or treating autoimmune neuritis;
[0043] Preferably, the autoimmune neuritis is experimental autoimmune neuritis.
[0044] Furthermore, the medicine is a medicine for preventing and / or treating Guillain-Barré syndrome.
[0045] Compared with the prior art, the present invention has the following beneficial effects:
[0046] (1) The bionic nanoliposome structure prepared by the present invention is similar to the cell membrane structure, both of which are composed of phospholipids and cholesterol, and are relatively safe. As a drug carrier, it will not produce toxic / side effects on the body;
[0047] (2) The biomimetic nanoliposomes prepared by the present invention are loaded with cystosporin B (CSNB) and salidroside (SAL). The immunomodulatory effect of CSNB and the neuroproliferation-promoting effect of SAL can achieve the purpose of immune balance and nerve repair, thereby alleviating the progression of experimental autoimmune neuritis;
[0048] (3) The present invention modifies the cell membrane of macrophages on the surface of liposomes to avoid the surveillance of the reticuloendothelial phagocytic system, increase the stability of liposomes in the blood, and prolong the circulation half-life of drugs. At the same time, the liposomes of the present invention improve the targeting by modifying phospholipidated hyaluronic acid, thereby maximizing the preventive and therapeutic effects of experimental autoimmune neuritis;
[0049] (4) The present invention solves the problems of low in vivo bioavailability and drug toxicity of CSNB and SAL, and provides new theoretical support for the development of new agents for the prevention and treatment of experimental autoimmune neuritis and related clinical prevention and treatment. It has original innovation, good social and economic benefits and broad application prospects, and can provide a theoretical basis for future clinical transformation.
[0050] In summary, the present invention provides a bionic nanoliposome targeting experimental autoimmune neuritis, which simultaneously encapsulates cystosporin B (CSNB) and salidroside (SAL), and while having a bionic membrane immune escape effect, can deliver CSNB and SAL to the inflammatory nerve site in a targeted manner, promote the recovery of damaged peripheral nerves while regulating immune balance, alleviate the occurrence and development of experimental autoimmune neuritis, and thus treat the damaged site of experimental autoimmune neuritis in a targeted manner. The bionic nanoliposome of the present invention can also prolong the half-life of the drug, improve the bioavailability of the drug, reduce the toxic and side effects of the drug on the body, and has better safety when used. Therefore, the bionic nanoliposome of the present invention is expected to be used for the prevention and treatment of autoimmune neuritis diseases (such as Guillain-Barre syndrome), and has good clinical application prospects.
[0051] Obviously, according to the above contents of the present invention, in accordance with common technical knowledge and customary means in the art, without departing from the above basic technical ideas of the present invention, other various forms of modification, replacement or change may be made.
[0052] The above contents of the present invention are further described in detail below through specific implementation methods in the form of embodiments. However, this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples. All technologies realized based on the above contents of the present invention belong to the scope of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0053] Figure 1 Transmission electron microscopy images of liposomes Lipo@CS (LCS) and HA-M@Lipo@CS (HMLCS) prepared in Example 1.
[0054] Figure 2 Lipo, Lipo@CS (LCS), M@Lipo@CS (MLCS) and HA-M@Lipo@CS (HMLCS) prepared in Example 1 1:20 、HMLCS 1:40 、HMLCS 1:60 )'s particle size and zeta potential diagram.
[0055] Figure 3 The graph shows the uptake results of liposomes LCS, MLCS and HMLCS prepared in Example 1 by activated macrophages.
[0056] Figure 4 This is a graph showing the results of HA-M@Lipo@CS prepared in Example 1 clearing active oxygen in macrophages.
[0057] Figure 5 This is a graph showing the results of HA-M@Lipo@CS prepared in Example 1 promoting the proliferation of neural cells.
[0058] Figure 6 Biomimetic nanoliposome HML ICG Blood half-life in mice.
[0059] Figure 7 Biomimetic nanoliposome HML ICG Targeting of inflammatory neural sites in rats.
[0060] Figure 8 These are the results of LFB staining and H&E staining of the sciatic nerve after the HA-M@Lipo@CS prepared in Example 1 treated experimental autoimmune neuritis (EAN).
[0061] Fig. 9 These are the results of HE staining of various organs in different treatment groups after treatment of experimental autoimmune neuritis.
[0062] Fig.10 This is a graph showing the effect of the mass ratio of cystosporin B (CSNB) and salidroside (SAL) to soybean lecithin on the encapsulation efficiency in the bionic nanoliposomes of the present invention. DETAILED DESCRIPTION
[0063] Unless otherwise specified, the raw materials and equipment used in the specific embodiments of the present invention are all known products and are obtained by purchasing commercially available products.
[0064] Example 1. Preparation and characterization of biomimetic nanoliposomes of the present invention
[0065] 1. Preparation of biomimetic nanoliposomes (HA-M@Lipo@CS) of the present invention
[0066] (1) Preparation of biomimetic cell membrane (M)
[0067] When the RAW264.7 cells in the cell culture dish were full, the cells were scraped off with a cell scraper and centrifuged; the collected cells were washed three times with 4°C PBS (pH 7.4) and then suspended in 4°C TM buffer solution containing phenylmethylsulfonyl fluoride (PMSF, 1 mM) (TM buffer configuration: 0.01 mol / L Tris, 0.001 mol / L MgCl 2 ), adjust the cell density to 2.5*10 7 / ml, incubate on ice for 30 minutes, and then treat in an ultrasonic cell disruptor for 5 minutes (power 40-80W). Then add 1 mol / L sucrose aqueous solution to obtain a cell suspension with a final sucrose concentration of 0.25 mol / L. Place it in liquid nitrogen and 37°C water bath and freeze and thaw it repeatedly for 3 times to fully disrupt the cells. Centrifuge (4°C, 2000g, 10min) to take the supernatant, continue to centrifuge the supernatant (4°C, 13600rpm, 30min), add 4°C TM buffer solution containing 0.25 mol / L sucrose to the obtained precipitate and resuspend it, and centrifuge to obtain macrophage membrane.
[0068] (2) Preparation of nanoliposomes Lipo@CS
[0069] Weigh 10 mg of soybean lecithin, 5 mg of cholesterol, and 1 mg of cystosporin B (CSNB) and mix them and dissolve them in 5 ml of chloroform; evaporate the mixture under reduced pressure in a rotary evaporator to remove the organic solvent, and after forming a dry film state, add 5 mL of PBS buffer (pH = 7.4) dissolved with salidroside (1 mg / ml) for hydration, rotate and hydrate until the film on the bottle wall is fully hydrated, pass through a 0.22 μm microporous filter membrane, and centrifuge to remove unencapsulated free drugs. The precipitate is the nanoliposome Lipo@CS (LCS) that meets the requirements.
[0070] (3) Preparation of nanoliposomes M@Lipo@CS
[0071] The macrophage membrane obtained in step (1) was dissolved in PBS buffer (pH = 7.4) to 1 mg / ml, and the Lipo@CS obtained in step (2) was mixed with the macrophage membrane (M) treated with water bath ultrasound at a mass ratio (mass ratio of soybean lecithin to macrophage membrane in Lipo@CS) of 10:1, and stirred in a water bath at 800 rpm for 1 hour at 37°C to obtain nanoliposomes M@Lipo@CS (MLCS).
[0072] (4) Preparation of biomimetic nanoliposomes HA-M@Lipo@CS
[0073] Preparation method of phospholipidated hyaluronic acid: 25 mg 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), 50 mg N-hydroxysuccinimide (NHS) and 5 mg hyaluronic acid (HA) were added to 1 ml PBS buffer, stirred at 25 °C for 30 min, and then 25 mg DSPE-PEG2000-NH 2 The mixed solution was stirred at 37°C for 30 min and then at 25°C for 24 h. The solution was placed in a dialysis membrane (molecular weight cutoff of 2.5 KD) and dialyzed in PBS buffer to remove free NHS and EDC, and then freeze-dried to obtain phospholipidated hyaluronic acid.
[0074] The M@Lipo@CS solution was mixed with phospholipidated hyaluronic acid in a mass ratio of 20:1 (mass ratio of soybean lecithin and phospholipidated hyaluronic acid in M@Lipo@CS), and stirred in a water bath at 800 rpm for half an hour at 37°C to obtain biomimetic nanoliposomes HA-M@Lipo@CS (HMLCS).
[0075] In addition, the method for preparing blank liposomes is as follows: weigh 10 mg of soybean lecithin and 5 mg of cholesterol, mix and dissolve in 5 ml of chloroform; evaporate the mixture under reduced pressure in a rotary evaporator to remove the organic solvent, and after forming a dry film state, add 5 ml of PBS buffer (pH = 7.4) for hydration, rotate and hydrate until the film on the bottle wall is fully hydrated, and pass through a 0.22 μm microporous filter membrane to obtain blank liposomes (Lipo).
[0076] 2. Characterization of the biomimetic nanoliposomes (HA-M@Lipo@CS) of the present invention
[0077] The morphology of Lipo@CS (LCS) prepared in step (2) and HA-M@Lipo@CS (HMLCS) prepared in step (4) was characterized by transmission electron microscopy. Figure 1 As shown, the obtained liposome LCS is a spherical nanoparticle with a particle size of 191.5 nm and a dispersion index (Pdi) of 0.137, and the liposome HMLCS is a spherical nanoparticle with a particle size of 180.4 and a dispersion index (Pdi) of 0.152, indicating that the present invention successfully synthesizes uniform and stable liposomes.
[0078] The prepared Lipo, LCS, MLCS and HMLCS (HMLCS was prepared according to the above method and using phospholipidated hyaluronic acid and soybean lecithin in different mass ratios, the mass ratios of phospholipidated hyaluronic acid and soybean lecithin were 1:20, 1:40 and 1:60, respectively, to prepare HMLCS 1:20 、HMLCS 1:40 、HMLCS 1:60 ) was used to analyze the particle size and Zeta potential by dynamic light scattering (DLS). Figure 2 It can be seen that the liposomes prepared by the present invention are all negatively charged, indicating that the prepared liposomes have good stability. At the same time, the HMLCS prepared by the mass ratio of phospholipidated hyaluronic acid and soybean lecithin is 1:20 has the smallest particle size. At this time, the nanoliposomes are more conducive to penetrating the blood-nerve barrier to achieve the purpose of effectively treating EAN. Therefore, the HMLCS prepared by the mass ratio of phospholipidated hyaluronic acid and soybean lecithin is 1:20 is the best. The HA-M@Lipo@CS (HMLCS) used in the following test examples are all HMLCS prepared by the mass ratio of phospholipidated hyaluronic acid and soybean lecithin is 1:20.
[0079] The beneficial effects of the present invention are demonstrated below through specific test examples.
[0080] Experimental Example 1: Study on the Cellular Uptake Ability of the Biomimetic Nanoliposomes of the Present Invention
[0081] The cell uptake ability of the liposomes Lipo@CS (LCS), M@Lipo@CS (MLCS) and HA-M@Lipo@CS (HMLCS) prepared in Example 1 was studied. The drug-loaded liposomes and the nanoliposomes wrapped by the biomimetic macrophage membrane were labeled with Dil, respectively, and incubated with activated RAW264.7 cells for 4 hours, and the uptake of the biomimetic nanoliposomes by the cells was observed using a confocal microscope.
[0082] The activated RAW264.7 cells were obtained by stimulating the RAW264.7 cells with lipopolysaccharide (LPS) at a concentration of 100 ng / ml for 24 hours, and the drug was added for the experiment 24 hours after the stimulation.
[0083] After successfully preparing Lipo@CS (LCS), M@Lipo@CS (MLCS) and HA-M@Lipo@CS (HMLCS), Dil dye was added and stirred at 800 pm for 2 hours in a 37°C water bath to obtain Dil-labeled nanoliposomes. The prepared Dil-labeled nanoliposomes were added to activated RAW264.7 cells and incubated for 4 hours for observation.
[0084] HA Solution+HMLCS@Dil: 0.5 mg / ml hyaluronic acid (HA) was added to the activated RAW264.7 cells for pretreatment for 1 hour, and then HMLCS@Dil was added and incubated for 4 hours before observation.
[0085] like Figure 3 As shown, activated RAW264.7 cells have the strongest uptake capacity for HA-M@Lipo@CS, and their uptake capacity is weakened after pre-blocking with hyaluronic acid (HA). The above results show that the HA-M@Lipo@CS biomimetic nanoliposomes prepared in Example 1 have the ability to actively target inflammatory macrophages.
[0086] Experimental Example 2: Study on the scavenging ability of biomimetic nanoliposomes of the present invention on active oxygen
[0087] RAW264.7 cells were used to study the scavenging ability of liposomes on reactive oxygen species. The experiment was divided into four groups: Control, Model, CS, and HMLCS. The cells in each group were treated as follows:
[0088] Control group: RAW264.7 cells were not treated in any way. DCFH-DA probe was added to the cells at the same time as the CS group and HMLCS group after drug intervention and incubated for 30 minutes, and then observed under a confocal microscope.
[0089] Model group: RAW264.7 cells were stimulated with lipopolysaccharide (LPS) at a concentration of 500 ng / ml for 4 hours, and DCFH-DA probe was added to the cells at the same time after drug intervention in the CS group and HMLCS group, incubated for 30 minutes, and observed under a confocal microscope.
[0090] CS group: 4 μM cystosporin B and 20 μM salidroside were added to RAW264.7 cells for 2 hours, and then RAW264.7 cells were stimulated with 500 ng / ml LPS for 4 hours; DCFH-DA probe was added and incubated for 30 minutes and observed under a confocal microscope.
[0091] HMLCS group: HMLCS prepared in Example 1 (capsosporin B concentration of 4 μM, salidroside concentration of 20 μM) was added to RAW264.7 cells for 2 hours, and then RAW264.7 cells were stimulated with LPS at a concentration of 500 ng / ml for 4 hours; DCFH-DA probe was then added and incubated for 30 minutes and observed under a confocal microscope.
[0092] like Figure 4 As shown, the HA-M@Lipo@CS bionic nanodrug prepared in Example 1 was added to LPS-intervention macrophages, and the scavenging ability of HA-M@Lipo@CS on reactive oxygen species was observed by immunofluorescence. The results showed that HA-M@Lipo@CS could significantly reduce the ROS expression of inflammatory macrophages to a level similar to that of normal RAW264.7 cells, and the effect was better than the combined use of capsodium salidroside and salidroside.
[0093] Experimental Example 3: Study on the Effect of the Biomimetic Nanoliposomes of the Present Invention on the Proliferation of Neuronal Cells
[0094] RSC96 cells were used to study the effect of liposomes on cell proliferation under oxidative stress. The experiment was divided into four groups: Control, Model, CS and HMLCS. The cells in each group were treated as follows:
[0095] Control group: RSC96 cells were not treated in any way, and the Edu kit was used to detect cell proliferation 24 hours after the HMLCS group was treated.
[0096] Model group: H 2 O 2RSC96 cells were treated for 2 hours, and the Edu kit was used to detect cell proliferation after the HMLCS group was treated for 24 hours.
[0097] CS group: 200 μM H 2 O 2 After treating RSC96 cells for 2 hours, 4 μM of cystosporin B and 20 μM of salidroside were added to RSC96 cells simultaneously for 24 hours, and then the cell proliferation was detected using the Edu kit.
[0098] HMLCS group: H 2 O 2 After treating the RSC96 cells for 2 hours, HMLCS (capsosporin B concentration of 4 μM, salidroside concentration of 20 μM) prepared in Example 1 was added to the RSC96 cells for 24 hours, and then the cell proliferation was detected using the Edu kit.
[0099] Proliferation of RSC96 cells under oxidative stress Figure 5 As shown: Compared with normal RSC96 cells (Control), the proliferation of RSC96 cells was affected under oxidative stress. The combined use of cystosporin B and salidroside or the use of HA-M@Lipo@CS could promote the proliferation of nerve cells (RSC96 cells), and the effect of HA-M@Lipo@CS (HMLCS) in promoting the proliferation of nerve cells was significantly better than the combined use of cystosporin B and salidroside.
[0100] Experimental Example 4: Blood half-life and in vivo targeting test of the biomimetic nanoliposomes of the present invention in mice
[0101] The blood half-life of the bionic nanoliposomes of the present invention in mice and the in vivo targeting of the EAN model were tested by in vivo imaging of small animals and detection of fluorescence intensity.
[0102] Experiment 1: Indocyanine green (ICG), HA-M@Lipo@ICG (HML ICG ) Kunming mice were injected with 3 mg / kg (ICG amount) through the tail vein, and blood samples were collected from the eye sockets at different time points (0h, 0.5h, 1h, 2h, 4h, 8h, 12h and 24h) for fluorescence intensity measurement. The results are shown in Figure 6 As shown, HML ICG The fluorescence of the liposome group was significantly prolonged compared with the ICG group, indicating that the bionic nanoliposomes prepared by the present invention significantly prolonged the half-life of the drug in vivo.
[0103] Among them, HA-M@Lipo@ICG was prepared by the following method (similar to Example 1, only for the convenience of observation, the nanomaterial was labeled with ICG): 20 mg of soybean lecithin, 10 mg of cholesterol, and 5 mg of ICG were mixed in 5 ml of chloroform and fully dissolved and mixed, then added to a round-bottomed flask in a rotary evaporator at 37°C and decompressed until a uniform film was formed, and then 5 ml of PBS buffer (pH = 7.4) was added for hydration to obtain Lipo@ICG. 200 μl of macrophage membrane (10 mg / ml) was added to the Lipo@ICG solution, and the mass ratio of soybean lecithin to macrophage membrane in Lipo@ICG was 10:1. The mixture was stirred at 37°C 800-1000 rpm for 2 hours to obtain M@Lipo@ICG. Finally, 200 μl of phospholipid hyaluronic acid (5 mg / ml) was added to the M@Lipo@ICG solution. The mass ratio of soybean lecithin to phospholipid hyaluronic acid in M@Lipo@ICG was 20:1. The mixture was stirred at 800-1000 rpm at 37°C for 1 hour to obtain HA-M@Lipo@ICG (HML ICG ). 1 mg / ml ICG was also prepared for control experiment.
[0104] Experiment 2: Experimental autoimmune neuritis (EAN) model was established in Lewis rats by injecting artificial peripheral nerve myelin protein P2 57-81 Peptide 400 μg, PBS 100 μL, Mycobacterium tuberculosis H37Ra 2 mg, IFA 100 μL were mixed, shaken thoroughly, and placed on ice and fully emulsified with an ultrasonic disruptor until it was uniform and viscous milky white. At the time of immunization (the day of immunization was day 0), the base of the Lewis rat's tail was disinfected on both sides, and a microsyringe was used to inject 100 μL of antigen emulsion into each side of the base of the rat's tail and press the puncture point to prevent the antigen emulsion from flowing out, a total of 200 μL / rat. After Lewis rat modeling, ICG and HA-M@Lipo@ICG (ICG amount was 3 mg / Kg) were injected into the tail vein at the peak of the disease (16th day after immunization). 4 hours later, the rat sciatic nerve was taken for fluorescence imaging. The results are as follows Figure 7 As shown, ICG and HA-M@Lipo@ICG (HML ICG ) group, the HA-M@Lipo@ICG group significantly aggregated in the sciatic nerve, indicating that the bionic nanoliposomes synthesized in the present invention can effectively target the inflammatory nerve sites.
[0105] Experimental Example 5: Evaluation of the therapeutic efficacy of the biomimetic nanoliposomes of the present invention in treating the experimental autoimmune neuritis (EAN) model
[0106] Experimental methods:
[0107] Normal Lewis rats were injected with peripheral nerve myelin protein P2 at the base of the tail 57-81 The emulsifier of the peptide segment was used as the control group (Control), which was injected with an emulsifier mixed with PBS 100 μL, H37Ra 2 mg and IFA 100 μL. The remaining Lewis rats were divided into three groups (Model group, CS group and HMLCS group) after the EAN model was established according to the method described in Experimental Example 4. Each group was treated as follows:
[0108] After the CS group was successfully modeled, medication was started on the 10th day after immunization, and 10 mg / kg CSNB and 50 mg / kg SAL were administered through the tail vein at the same time, every other day, for a total of 7 times;
[0109] After the HMLCS group was successfully modeled, medication was started on the 10th day after immunization, and HMLCS prepared in Example 1 (CSNB concentration was 10 mg / kg, SAL concentration was 50 mg / kg) was administered through the tail vein, and the medication was given every other day for a total of 7 times;
[0110] After the model group was successfully established, an equal amount of PBS was given through the tail vein starting on the 10th day of immunization, and PBS was given every other day for a total of 7 times;
[0111] The control group was given an equal amount of PBS directly through the tail vein at the same time and every other day, for a total of 7 times.
[0112] After each group was given drug or PBS, the rats were killed on the 26th day after immunization, and the sciatic nerves were obtained for LFB and H&E staining.
[0113] Experimental results:
[0114] like Figure 8 As shown, after HA-M@Lipo@CS (HMLCS) treatment, the LFB staining area of the sciatic nerve of rats increased significantly, and H&E staining showed that the inflammatory cell infiltration of the sciatic nerve decreased, and the effect was significantly better than the combined use of cystosporine B and salidroside group.
[0115] Test Example 6: Safety evaluation of the biomimetic nanoliposomes of the present invention in treating an experimental autoimmune neuritis model
[0116] Experimental methods:
[0117] The treatment was carried out according to the method described in Experimental Example 5. The rats were killed and their main organs (heart, liver, spleen, lung and kidney) were taken for H&E staining to investigate the biological safety of different treatment groups.
[0118] Experimental results:
[0119] The results are as follows Fig. 9As shown, no obvious organic lesions were found in the organs of rats in different treatment groups, indicating that the bionic nanoliposomes constructed by the present invention have good biosafety.
[0120] Experimental Example 7: Effect of the mass ratio of cytosporin B (CSNB) and salidroside (SAL) to soybean lecithin on the encapsulation efficiency in the biomimetic nanoliposomes of the present invention
[0121] HA-M@Lipo@CS was prepared according to the method described in Example 1, except that the amount of cytosporin B (CSNB) or salidroside (SAL) was changed when preparing Lipo@CS. When the amount of cytosporin B (CSNB) was changed, the mass ratio of soybean lecithin to CSNB was 5:1, 10:1, 15:1 and 20:1, and when the amount of salidroside (SAL) was changed, the mass ratio of soybean lecithin to SAL was 1:1, 2:1, 3:1 and 4:1. The encapsulation efficiency of the prepared HA-M@Lipo@CS was measured, and the results were as follows: Fig.10 shown.
[0122] The inventor's previous research showed that when the mass ratio of SAL to CSNB was 5:1, the drug efficacy was optimal. Fig.10 Based on the encapsulation efficiency results, the mass ratio of soybean lecithin to SAL was 2:1, and the mass ratio of soybean lecithin to CSNB was 10:1 for the preparation of liposomes.
[0123] In summary, the present invention provides a bionic nanoliposome targeting experimental autoimmune neuritis, which simultaneously encapsulates cystosporin B (CSNB) and salidroside (SAL), and while having a bionic membrane immune escape effect, can deliver CSNB and SAL to the inflammatory nerve site in a targeted manner, promote the recovery of damaged peripheral nerves while regulating immune balance, alleviate the occurrence and development of experimental autoimmune neuritis, and thus treat the damaged site of experimental autoimmune neuritis in a targeted manner. The bionic nanoliposome of the present invention can also prolong the half-life of the drug, improve the bioavailability of the drug, reduce the toxic and side effects of the drug on the body, and has better safety when used. Therefore, the bionic nanoliposome of the present invention is expected to be used for the prevention and treatment of autoimmune neuritis diseases (such as Guillain-Barre syndrome), and has good clinical application prospects.
Claims
1. A biomimetic nanoliposome targeting experimental autoimmune neuritis, characterized in that: It is prepared by wrapping a bionic cell membrane with the outer layer of liposomes carrying cystosporin B and salidroside, and then modifying the surface of the bionic cell membrane with phospholipidated hyaluronic acid.
2. The biomimetic nanoliposome according to claim 1, characterized in that: The preparation method of the liposome containing cystosporin B and salidroside comprises the following steps: (1) dissolving soybean lecithin, cholesterol and cystosporin B in an organic solvent, and removing the organic solvent after rotary evaporation to obtain a film; (2) Adding a hydrating medium containing salidroside into the film for hydration to obtain the film.
3. The biomimetic nanoliposome according to claim 2, characterized in that: In step (1), the mass ratio of soybean lecithin to cholesterol is (2-4):1; And / or, in step (1), the mass ratio of soybean lecithin to cystosporin B is (5-20):1; And / or, in step (1), the organic solvent is chloroform or methanol; And / or, in step (2), the mass ratio of salidroside to the soybean lecithin in step (1) is 1:(1-4); And / or, in step (2), the volume mass ratio of the hydration medium containing salidroside to soybean lecithin is (1-4) ml:2 mg; Preferably, In step (1), the mass ratio of soybean lecithin to cholesterol is 2:1; And / or, in step (1), the mass ratio of soybean lecithin to cystosporin B is 10:1; And / or, in step (2), the mass ratio of salidroside to the soybean lecithin in step (1) is 1:2; And / or, in step (2), the volume mass ratio of the hydration medium containing salidroside to soybean lecithin is 1 ml:2 mg.
4. The biomimetic nanoliposome according to claim 3, characterized in that: In step (2), the hydration medium is a phosphate buffer with a pH of 7.4; And / or, in step (2), after hydration, the solution is filtered through a microporous filter membrane with a particle size of 0.22 μm.
5. The biomimetic nanoliposome according to claim 1, characterized in that: The bionic cell membrane is a macrophage membrane.
6. The biomimetic nanoliposome according to claim 1, characterized in that: The preparation method of the phospholipidated hyaluronic acid comprises the following steps: Dissolve hyaluronic acid, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide, N-hydroxysuccinimide and DSPE-PEG2000-NH2 in PBS buffer and stir to react, dialyze and freeze-dry to obtain; Preferably, The mass ratio of the hyaluronic acid, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, N-hydroxysuccinimide and DSPE-PEG2000-NH2 is 1:(1-5):(1-10):5; And / or, the reaction temperature is 25-40°C.
7. A method for preparing the biomimetic nanoliposome according to any one of claims 1 to 6, characterized in that: It includes the following steps: 1) mixing the liposomes loaded with cystosporin B and salidroside with the PBS buffer of the bionic cell membrane and stirring to obtain the liposomes with the outer layer wrapped with the bionic cell membrane; 2) Mix the liposomes with the bionic cell membrane wrapped in the outer layer with the PBS buffer solution of phospholipidated hyaluronic acid and stir to obtain a liposome.
8. The method according to claim 7, characterized in that: In step 1), the mass ratio of soybean lecithin to bionic cell membrane in the liposome is (10-20):1; And / or, in step 1), the stirring temperature is 25-37° C., the rotation speed is 800-1000 rpm, and the time is 1-4 hours; And / or, in step 2), the mass ratio of soybean lecithin to phospholipidated hyaluronic acid in the liposome is (20-60):1; And / or, in step 2), the stirring temperature is 25-37°C, the rotation speed is 800-1000 rpm, and the time is 0.5-2 hours; Preferably, In step 1), the mass ratio of soybean lecithin to bionic cell membrane in the liposome is 10:1; And / or, in step 2), the mass ratio of soybean lecithin to phospholipidated hyaluronic acid in the liposome is 20:
1.
9. Use of the biomimetic nanoliposome according to any one of claims 1 to 6 in the preparation of a drug for preventing and / or treating autoimmune neuritis; Preferably, the autoimmune neuritis is experimental autoimmune neuritis.
10. The use according to claim 9, characterized in that: The medicine is a medicine for preventing and / or treating Guillain-Barré syndrome.
Citation Information
Cited By
Nanoparticle TK-PSBs / CBD-Met and preparation method and application thereof
CN120661487A
Nanoparticle TK-PSBs / CBD@Met, preparation method and application thereof
CN120661487B
